The One Development-Stage Drug Stock to Own Now
21611
One undervalued drug developer may be on the cusp of greatness.
250519
The brand is great. The stock is another story.
223632
Molecular Insight Pharmaceuticals, Inc. announced today the pricing of  its initial public offering of 5.0 million shares of common stock at a  price of $14.00 per share. All of the shares are being sold by  Molecular Insight.
597596
A word of advice: You should own these stocks for the long haul.
727152
New developments are brewing at the pharmaceutical.
714241
Synta Pharmaceuticals Corp. knows a thing or two about developing drugs. It has pretty impressive skills when it comes to money, too.
519863
The company faces a pivotal clinical trial.
642953
One new stock has left quite a footprint.
459925
A stock for dividend investors' watch list.
488185
Play the market with these stocks.
522708
It's the most important stock you can own.
190859
Lots of financial stocks represent excellent value right now. Here are the ones who should do the best.
439056
The generics drugmaker forecasts its 2008 financials.
264861
Osteoporosis drug could give the company its next big winner.
81346
Never considered drug stocks? You're missing some of the market's best investments.
738382
The drug maker is poised to speed past its rivals.
264619
First, let me gloat.  I bought $49,761 of AAPL on Oct 8.  My investment is now worth $54,933. That's 10.5 percent growth in less than a month. Hah! I bought the stock because I was going to buy everything Apple sold from now until forever. The last product I had yet to purchase was the company's stock. That was a mistake. The beauty of owning the stock is that you can use the increase in value to fund the hardware habit. So far so good.  My very dear friend Sylvia Paull bought an iPod a month ago. In a blog post today she calls it a gateway drug. Having read early reviews of the new operating system, she's ready to buy a 24 inch iMac.  I recognize the signs.  It's like a virus I tell you.